Skip to main content
1006-2026
class com.aha.ucm.component.cis.TagListPageData=[,docNativeURL=null,docName=UCM_480207,docStatus=RELEASED,dOutDate=null,docSSFileName=UCM_480207_Scientific-Rationale-for-the-Inclusion-and-Exclusion-Criteria-for-IV-Alteplase-i.jsp,docTitle=Scientific Rationale for the Inclusion and Exclusion Criteria for IV Alteplase i,xWebsites=professional,dDocAuthor=t-amy.achilles-stefa,xNextReviewDate=09/22/2016 5:42 PM,xTier1=36,xFeaturedItem=No,xElectronicRegistration=No,UserLocale=null,xSubCategory=,dpEvent=null,xComments=Scientific Rationale for the Inclusion and Exclusion Criteria for IV Alteplase in Acute Ischemic Stroke (AIS) shows that while numerous studies and registry data affirm the effectiveness of IV alteplase in AIS, only a minority (3-5%) of patients receive the drug.,NoHttpHeaders=null,UserTimeZone=null,xRegionDefinition=GENERIC_RD_COL_1,xVideoRenditions=,xSnippetItem=,xNotes=autoconverted |,UserDateFormat=null,encodeDocUrl=null,isDocProfileDone=null,xKeywords=brain ischemia; cerebral infarction; fibrinolytic agents; stroke; thrombolytic therapy; tissue plasminogen activator,xTier2=,refreshSubMonikers=null,xEditorStepReassignedUsers=null,xLinkTextToDisplay=,dDocAccount=WCM/SOP/SMD,xEndDateTime=null,xClbraAliasList=null,ClientEncoding=null,xCpdIsLocked=0,xUsageRightsDate=null,xModifyDate=08/17/2017 4:49 PM,xTier3=,xEventDate=null,dSubscriptionType=null,xCopyright=No,xPackagedConversions=,dSubscriptionAlias=null,xStorageRule=,dpName=null,xDepartment=Science Operations,dStatus=RELEASED,dPublishType=,xCopyrightDetails=,xSubType=64,isDocProfileUsed=null,xWebsiteObjectType=Data File,xWebFlag=,xSeeAlsoLinks=,xClbraUserList=null,xPartitionId=,xCpdIsTemplateEnabled=0,xLinkWebAddress=,xDontShowInListsForWebsites=,xStartDateTime=null,dInDate=08/17/2017 4:48 PM,xWebsiteSection=professional:1463,dDocName=UCM_480207,dpAction=null,dRevLabel=15,dSecurityGroup=AHAMAH-Public,xCategory=,refreshMonikers=null,xDamConversionType=,dDocFormats=null,xAssociatedImage=,dDocType=SingleColumn,xBusinessOwner=Business Owner,xUploadDate=null,xDiscussionCount=0,xMainFlowEntryCriteria=True,xItemInformation=,xUsageRights=,xDiscussionType=N/A,xRecipeTaxonomy=,dSubscriptionID=null,dOriginalName=UCM_480207.xml,xProfileTrigger=SingleColumn,dLocation=,dRevisionID=8,dPublishState=,dReleaseState=Y,xTrashDeleter=null,dMessage=,dWebExtension=xml,dExtension=xml,dProcessingState=Y,xTrashDeleteName=null,dIsCheckedOut=0,xForceFolderSecurity=null,dRevClassID=480207,dIsPrimary=1,dFileSize=13003,dIndexerState=,dFlag1=,xviaAddNewContentService=,dIsWebFormat=0,xCollectionID=null,dRevRank=0,xReadOnly=null,dCheckoutUser=,dFormat=Application/xml,dWorkflowState=,dDocID=1773846,dRendition2=,dRendition1=,xInhibitUpdate=null,dReleaseDate=08/17/2017 5:17 PM,xTrashDeleteLoc=null,dCreateDate=08/17/2017 4:49 PM,xHidden=null,labelTier1=ScienceNews,labelTier2=,labelTier3=,labelTier4=,mobileNavURL=DEFAULT2_VALUE_FROM_getDataForAdvanceSearch,xContactPhoneNumber=,xContactEmailAddress=,xContactName=,xATGRolesDisciplines=,xPublishDate=12/22/2015 6:00 AM,xRobotParameter=,xCommunities=1006-2026,xMembershipLevel=,rsCalories=null,rsSodium=null,rsRecipeTaxonomy=null,rsServings=null,rsTotalTime=null,rsTotalFat=null,rsTotalCarbs=null,rsFeaturedImage=null,xDisplayComments=

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke (AIS)

  • While numerous studies and registry data affirm the effectiveness of IV alteplase in AIS, only a minority (3-5%) of patients receive the drug.
  • Many of the current exclusions for alteplase are controversial to many stroke experts, with many considering them to be relative or absolute.
  • This statement is meant to be adjunctive to the 2013 Acute Ischemic stroke Guidelines.